Category Archives: Cancer

Eric Lefkofsky Has Made A Difference In The Way Cancer Is Treated

Cancer is a serious disease and affects a large portion of adults living in the United States. Eric Lefkofsky believes the answer is in data-enabled precision medicine and it was for this reason he co-founded Tempus. There has been a lot of talk about electronic health records in the world of medicine but the modern technology in the field is not as advanced as it could be. Tempus comes into play with their platform to effectively analyze all the data of a patient. The molecular and clinical data is crucial in the way cancer is treated. One the structured data is readily available to the medical world the treatment and care received by cancer patients can be advanced.

Human genome sequencing is used to gather an individual’s genomic information. This process is not new but advancements in technology and science have substantially lowered the once astronomical cost. Eric Lefkofsky uses this data because it holds the secrets of the human genes. When this data is combined with the molecular and clinical data of a patient it makes fighting many diseases including cancer easier. The more data that is analyzed the clearer the picture becomes to the researchers. Through the information provided by Tempus and other technological research facilities physicians will eventually be able to make a specific pairing between a cancer patient and the treatment that will produce the best results for their exact situation. Ineffective treatments can be eliminated and the more effective treatments further researched.

The journey taken by Eric Lefkofsky before Tempus began in 1969. His life began in Michigan and his accomplishments already rival the success of a lifetime. Shortly after he had completed his education it was obvious he was a major power player. Instead of going into the field of law as he initially intended he became involved in the revolution of the For more info about us: click here.

Eric Lefkofsky lives his life near Chicago and devotes a portion of his time helping local charities. He serves on the board for several of Chicago’s hospitals, museums, and theatres. He is an adjunct professor and has progressed the treatment of cancer through his passion, expertise, and dedication.

Eric Lefkofsky sees future of cancer treatment in genomic data

Eric Lefkofsky has become one of the nation’s most widely respected tech entrepreneurs. After founding Groupon, a company that allows individuals to become part of groups eligible for deep discounts on everything from pizza to hotel rooms, he went on to have a successful second career developing a string of successful startups.

But then, in 2013, Lefkofsky’s wife got a terrible diagnosis. She had advanced breast cancer. The Lefkofsky’s both put their heads down and charged the disease full-on. Over the course of the next year, Lefkofsky accompanied his wife to dozens of appointments. In the end, his wife was cured of the disease and, today, is a cancer survivor.

But Lefkofksy left the process of cancer treatment with the deep impression that things were not all well with the state of modern oncology. He noted that many of the oncologists who saw his wife did not have ready access to the best data and analytics, crucial tools that could provide key information to the treatment process. Lefkofsky decided to research ways in which all of the sources of oncologically relevant data could be put into the hands of oncologist, in ways that were digestible and informative to the decision makers.

In 2016 Eric Lefkofsky founded Tempus, a company dedicated to the provision of oncologists with key intelligence, which is mined from a vast number of primary data sources. The idea behind Tempus is to create a sort of on-demand meta-study capability, where interesting questions that oncologists may have regarding patient cohorts  treatment regimes can be answered in real time.

One of the most potent sources of largely untapped data is the human genome itself. Tempus is creating a system that will be able to use the genome of cancer patients to find relationships between genetics, comorbid conditions and data from studies and how these things affect treatment outcomes. Within the next decade, Lefkofsky sees the rapidly diminishing cost of sequencing the human genome as being the main driver of medical advances, with practically every future patient cohort having their entire genome completely sequenced. This will provide a level of understanding previously never imagined.

To learn more visit @: